SCHEMBL26985602

SCHEMBL26985602

COCCc1ncc(N2CCN(C(=O)OCc3ccccc3)CC2)cc1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMEM97 Q5BJF2 12/20 0.47
SIGMAR1 Q99720 12/20 0.47
HRH1 P35367 2/20 0.47
HRH3 Q9Y5N1 2/20 0.47
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
DRD1 P21728 1/20 0.47
HRH2 P25021 1/20 0.47
HTR1B P28222 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
HTR1E P28566 1/20 0.47
SLC6A4 P31645 1/20 0.47
HTR2B P41595 1/20 0.47
HDAC1 Q13547 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23296608 0.84 TMEM97 (0.47) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL23296610 0.84 TMEM97 (0.47) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL25889397 0.83 TMEM97 (0.49) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL31703435 0.83 TMEM97 (0.49) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL31703372 0.82 TMEM97 (0.48) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL31228353 0.77 TMEM97 (0.47) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL5230804 0.76 TMEM97 (0.52) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL25249577 0.76 NR1H2 (0.48) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL19212232 0.75 TMEM97 (0.57) TMEM97SIGMAR1HRH1HRH3HTR1A
SCHEMBL9727540 0.74 NPSR1 (0.68) TMEM97SIGMAR1HRH1HRH3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024008610-A1 MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2024-01-11 WO disclosed
WO-2023232776-A1 HALOINDOLE MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2023-12-07 WO disclosed